Relmada Therapeutics stock falls after $100 million share offering By Investing.com
Update: 2025-11-04
Description
Relmada Therapeutics, a biotech company, announced a $100 million share offering, causing a drop in share price. The funds will be used for operational costs and clinical trials, particularly for their bladder cancer drug candidate, NDV zero one. The drug showed promising results in a phase two trial, with an 85% complete response rate. Relmada plans to start phase three trials in 2026, aiming for approval in multiple bladder cancer indications. Major investment banks are assisting with the offering, and all eyes are on how Relmada will use the funds and if their cancer drug program can deliver significant breakthroughs.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
